NeoImmuneTech, Inc. (KOSDAQ:950220)

Market Cap	174.70B -69.0%
Revenue (ttm)	608.57M +231.4%
Net Income	-31.04B
EPS	-232.79
Shares Out	98.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,828,840
Open	2,095.00
Previous Close	2,505.00
Day's Range	1,755.00 - 2,150.00
52-Week Range	1,755.00 - 9,405.00
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About NeoImmuneTech

NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea. It is developing NT-I7, an IL-7 class T- cell amplifier to treat acute radiation syndrome; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 52
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950220

Financial Performance

In 2025, NeoImmuneTech's revenue was 94.82 million, a decrease of -44.35% compared to the previous year's 170.38 million. Losses were -31.80 billion, -22.23% less than in 2024.